|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 October 2017 |
|
Main ID: |
NCT01061866 |
|
Date of registration:
|
17/02/2009 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Thalidomide Low Threshold in Epilepsy
|
|
Scientific title:
|
Treatment of Refractory Epilepsy With Thalidomide: an Open Trial |
|
Date of first enrolment:
|
June 2006 |
|
Target sample size:
|
7 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT01061866 |
|
Study type:
|
Interventional |
|
Study design:
|
|
|
Phase:
|
Phase 1/Phase 2
|
|
|
Contacts
|
|
Name:
|
Julio Sotelo, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
National Institute of Neurology and Neurosurgery of Mexico |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Refractory Epilepsy, males
Exclusion Criteria:
- Females, peripheric neuropathy
Age minimum:
17 Years
Age maximum:
40 Years
Gender:
Male
|
|
Health Condition(s) or Problem(s) studied
|
|
Refractory Epilepsy
|
|
Intervention(s)
|
|
Drug: 3-phthalimidoglutarimide (Thalidomide)
|
|
Primary Outcome(s)
|
|
Change From Baseline in the Mean Number of Daily Seizures at 1 Year.
[Time Frame: Baseline 3 months and 1 year of treatment]
|
|
Secondary ID(s)
|
|
INNN 36/06
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|